Scalper1 News
Biotech investors always seem to be looking for the next big thing. These days, many are going under the hood of the CAR-T. CAR-T is short for chimeric antigen receptor T-cell therapy, a version of immunotherapy, which deploys the patient’s own immune system to fight cancer. First developed in academic labs, CAR-T therapies have been picked up by big pharma Novartis (NVS) as well as a number of small startups. Kite Pharma (KITE), Bluebird Bio Scalper1 News
Scalper1 News